About Prothea Technologies
Prothea Technologies is a company based in Edinburgh (United Kingdom) founded in 2024. Prothea Technologies has raised $12.67 million across 1 funding round from investors including NRW.Bank, Earlybird and Merieux Equity Partners. Prothea Technologies operates in a competitive market with competitors including Prana Thoracic, Selio Medical, Suzhou Lung Care Medical Technologies, Spiromagic and Cirrus Bio, among others.
- Headquarter Edinburgh, United Kingdom
- SectorsHealthcare
- Website prothea.tech
- Social LinkedIn
- Legal Name Prothea Technologies Limited
- Date of Incorporation 14 Jun, 2021
- Jurisdiction EDINBURGH, SCOTLAND
- Total Equity Funding$12.67M (USD)
in 1 rounds
- Latest Funding Round$12.67M (USD), Series A
Apr 2024
- InvestorsNRW.Bank
& 3 more
Funding Insights of Prothea Technologies
Prothea Technologies has successfully raised a total of $12.67M through 1 strategic funding round. The most recent funding activity was a Series A round of $12.67 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $12.67M
- Total Rounds 1
- Last Round Series A — $12.67M
- First Round $12.67M
(Apr 2024)
- Investors Count 4
All 1 funding rounds of Prothea Technologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2024 | $12.67M | Series A | – | Earlybird, Merieux Equity Partners |
4 investors in total: 4 institutional.
Investors in Prothea Technologies
Prothea Technologies has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include NRW.Bank, Earlybird and Merieux Equity Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Earlybird is recognized as a venture capital investor focused on early-stage tech companies. | – | earlybird.com | Berlin, Germany | |
Pivate equity firm that focuses on investing in healthcare and nutrition companies | – | merieux-partners.com | Lyon, France | |
- | – | oldcollegecapital.co.uk | - | |
Loans, advice, seminars, and networks are provided for financial support. | 2001 | nrwbank.de | Dusseldorf, Germany |
Investor details for Prothea Technologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Prothea Technologies
2 people are tracked at Prothea Technologies (2 in leadership).
| Name | Role | Group |
|---|---|---|
Crispin Simon | CEO | Leadership |
Kev Dhaliwal | Chief Scientific Officer/ Chief Medical Officer | Leadership |
Complete people profiles for Prothea Technologies
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Prothea Technologies
2 dated milestones of Prothea Technologies, from founding to its latest funding, stage changes and deals.
- Founded Prothea Technologies is founded.
- Funding First funding round of $12.7M.
Competitors of Prothea Technologies
Prothea Technologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Prana Thoracic, Selio Medical, Suzhou Lung Care Medical Technologies, Spiromagic and Cirrus Bio, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| pranathoracic.com | 2022 | Houston, United States | $6M | – | A company focused on early intervention in lung cancer. | |
| seliomedical.com | 2016 | Dublin, Ireland | – | – | Device developed to prevent pneumothorax during lung biopsies. | |
| lungcaremed.com | 2015 | Suzhou, China | – | – | A bronchoscope navigation system is developed using electromagnetic positioning technology. | |
| spiromagic.dk | 2014 | Gribskov, Denmark | $703,904 | 3 | Smartphone-connected spirometers are supplied for lung function assessment. | |
| cirrus.bio | 2021 | Phoenix, United States | – | – | Multi-omic solutions for disease diagnosis and management are developed. | |
| guide-xt.com | 2007 | Qiryat Shemona, Israel | – | – | Develops apparatus for accurate needle insertion in cancer diagnosis. | |
| nanomobilehealthcare.com | 2015 | New York, United States | – | – | Online marketplace for electronics, fashion, and household items shopping. |
Detailed competitors of Prothea Technologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Prothea Technologies
Complete news archive for Prothea Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Prothea Technologies
10 companies that operate in the same segment as Prothea Technologies (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Prothea Technologies
Prothea Technologies was founded in 2024.
Prothea Technologies is headquartered in Edinburgh, United Kingdom. It is registered at Edinburgh, Scotland, United Kingdom.
Crispin Simon is the current CEO of Prothea Technologies.
Prothea Technologies is a funded company, having raised a total of $12.67M across 1 funding round to date. The company's 1st funding round was a Series A of $12.67M, raised on Apr 2024.
Prothea Technologies was founded in 2024 in Edinburgh, United Kingdom. Medical devices for lung cancer biopsy and treatments are developed by the company within the healthcare sector. A microendoscope combined with an image processing system is being created to enable in situ analysis of lesion structures at a molecular level. Enhanced visualization during procedures is facilitated through this technology, with operations centered on diagnostic and therapeutic applications.
Prothea Technologies's top competitors include Prana Thoracic, Selio Medical and Spiromagic.
Prothea Technologies has 4 investors. Key investors include NRW.Bank, Earlybird, Merieux Equity Partners, and Old College Capital.
Prothea Technologies operates through Prothea Technologies Limited.